panitumumab,bevacizumab
amgen,takeda,roche
['panitumumab']
dr. yoshino lba1 #asco22: discontinuation rate for panitumumab was 23.8% vs. 18.4% for bev 
Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi